A phase I/II trial of concurrent cisplatin/etoposide/radiotherapy with sorafenib followed by consolidation sorafenib in patients with inoperable stage III non-small cell lung cancer (NSCLC): Hoosier Oncology Group LUN06-107.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary) ; Cisplatin; Etoposide
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

09 Apr 2008 Status change from recruiting to discontinued, as reported by clinicaltrials.gov, due to negative results from the ESCAPE trial and safety concerns.
10 Nov 2007 New trial centres added.
10 Nov 2007 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight